Medicine
Halaven 1 mg/2 mL injection
Halaven 1 mg/2 mL injection is a prescription medicine containing Eribulin for intravenous use, marketed by Eisai, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze or refrigerate. Store at 25°C (77°F), excursions permitted to…
Key facts
- Active ingredient (INN)
- Eribulin
- Brand
- Halaven
- Strength
- 1 mg/2 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 2 mL, 100 vials of 2 mL
- Marketing authorisation holder
- Eisai
- Manufacturers
- EisaiBSP Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Do not freeze or refrigerate. Store at 25°C (77°F), excursions permitted to 15° to 30° C (59° to 86° F). Store the vials in their original cartons.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XX41 Eribulin
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 November 2010
- Identifiers
- RxCUI 1045456, 1045460DailyMed set ID 31ce4750-ded5-4a0b-95e9-f229fa6bc822, 8fc8fe1d-59fe-4e43-a95c-e7aa13422cd6NDC 62856-389, 43624-002Application NDA201532
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 2 mL in 1 vial, single-dose | 62856-389-01 | Eisai | 15 November 2010 |
| 100 vial in 1 tray / 2 mL in 1 vial | 43624-002-01 | BSP Pharmaceuticals | 21 April 2017 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Eribulin 1 mg/2 mL injection.
Clinical summary
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease, among other approved uses. MedsAcross supplies Eribulin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about EribulinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Halaven prescribing information (Eisai) · U.S. National Library of Medicine, DailyMed
- Halaven: European public assessment report (EPAR) · European Medicines Agency
- Eribulin Baxter: European public assessment report (EPAR) · European Medicines Agency
Need Halaven 1 mg/2 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.